In a 416-patient multicenter RCT, exenatide uniquely reduced inflammatory cytokines IL-1β and IFN-γ over 48 weeks in newly diagnosed type 2 diabetes, while insulin actually increased them and pioglitazone had no effect.
416 patients, 25 centersLarge multicenter RCT showing exenatide reduced inflammation while insulin increased it over 48 weeks
What the researchers found
Exenatide significantly decreased IL-1β and IFN-γ levels over 48 weeks, while insulin increased both markers. The anti-inflammatory effect of exenatide was independent of changes in weight, waist circumference, and HbA1c, and was associated with improved insulin resistance.
Why it matters
Chronic low-grade inflammation drives many complications of type 2 diabetes. This large RCT shows that exenatide has anti-inflammatory properties beyond blood sugar control — a benefit that insulin and pioglitazone do not share, potentially favoring GLP-1 drugs as first-line therapy.
The numbers in context
416 patients from 25 centers. 48-week intervention. Three treatment arms compared for adipokine and inflammatory cytokine changes.
How the study worked
Post-hoc analysis of the CONFIDENCE trial: 416 newly diagnosed T2DM patients from 25 centers randomized to 48-week treatment with exenatide, insulin, or pioglitazone. Adipokines (leptin, FGF21) and inflammatory cytokines (IL-1β, IFN-γ) measured at baseline and study end.
Who was studied
Newly diagnosed T2DM patients from 25 Chinese centers
What this study cannot tell us
Post-hoc analysis — adipokine changes were not the primary trial endpoint. Chinese population only, limiting generalizability. Exenatide is an older, less potent GLP-1 agonist; newer drugs like semaglutide may show different patterns. 32% dropout rate over 48 weeks.
How to read the evidence
Moderate-to-strong evidence — post-hoc analysis of a well-designed, large multicenter RCT, but adipokine endpoints were not the primary outcome.
When this study was published
Published in 2024 as a secondary analysis of the CONFIDENCE trial, reflecting current understanding of GLP-1 agonist anti-inflammatory effects.
The bigger picture
The anti-inflammatory effects of GLP-1 receptor agonists may partly explain their cardiovascular and organ-protective benefits observed in large outcome trials. This study adds mechanistic evidence that GLP-1 drugs do more than lower blood sugar — they may actively reduce the inflammatory environment that drives diabetic complications.
Questions still open
- Do newer GLP-1 agonists like semaglutide and tirzepatide produce even stronger anti-inflammatory effects than exenatide?
- Could the inflammatory cytokine increase seen with insulin therapy contribute to worse long-term outcomes?
- Would combining exenatide with pioglitazone produce additive anti-inflammatory and insulin-sensitizing effects?
Common questions
Does exenatide reduce inflammation better than newer GLP-1 drugs like semaglutide?
Should I be concerned that insulin increased inflammatory markers?
Read the original research
Comparison of changes in adipokine and inflammatory cytokine levels in patients with newly diagnosed type 2 diabetes treated with exenatide, insulin, or pioglitazone: A post-hoc study of the CONFIDENCE trial.
Heliyon, 10(1), e23309
Citation
Yang, Xubin; Deng, Hongrong; Lv, Jing; Chen, Xueyan; Zeng, Longyi; Weng, Jianping; Liang, Hua; Xu, Wen. (2024). Comparison of changes in adipokine and inflammatory cytokine levels in patients with newly diagnosed type 2 diabetes treated with exenatide, insulin, or pioglitazone: A post-hoc study of the CONFIDENCE trial.. Heliyon, 10(1), e23309. https://doi.org/10.1016/j.heliyon.2023.e23309